New PrecisA Monoclonals for cancer research
Jun 2023
Nowadays, several approaches aim to understand the biology of diseases by identifying promising markers, which may provide effective novel therapies.
The identification of molecular biomarkers is unquestionably essential and urgent for an accurate prognosis and the development of critical therapeutic targets in cancer research. Therefore, we must expand our knowledge as a step toward the design of practical and safe treatments.
Atlas Antibodies released new PrecisA Monoclonals related to ovarian and glioma research.
Needs
- Specific and effective biomarkers able to identify early stages of the disease and reliable prognostic markers for predicting clinical responses as well as defining the divergent molecular pathways underlying the development of the disease.
- Protein-related data such as citations, application-specific validation and sequence information, and homology, are paramount in the buying process and the single biggest driver for antibody choice.
- A trusted source of data in order to feel confident in the purchase of new antibodies.
Why Atlas Antibodies?
- Atlas Antibodies continues searching for better early detection markers and new therapeutic targets.
- Over 12,000 product citations worldwide
- Application-specific Enhanced Validation
- Strong roots in the Human Protein Atlas
- Transparency & open-access data
Ovarian markers - new monoclonals antibodies
Ovarian cancer is the deadliest form of female gynecologic cancers causing more deaths than any other cancer of the female reproductive system.
Therefore, there is a high demand to identify biomarkers specific to this disease for screening for early detection, as well as new therapeutic targets. The capacity of these biomarkers to predict the existence, stages, and associated therapeutic efficacy of ovarian cancer would enable improvements in the early diagnosis and survival of ovarian cancer patients.
Discover new products: